228 related articles for article (PubMed ID: 2553435)
21. Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes.
Cruciani RA; Lutz RA; Munson PJ; Rodbard D
J Pharmacol Exp Ther; 1987 Jul; 242(1):15-20. PubMed ID: 3039108
[TBL] [Abstract][Full Text] [Related]
22. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
23. Modulation of mu-mediated antitussive activity in rats by a delta agonist.
Kamei J; Tanihara H; Kasuya Y
Eur J Pharmacol; 1991 Oct; 203(1):153-6. PubMed ID: 1665789
[TBL] [Abstract][Full Text] [Related]
24. Studies of morphine and D-ala2-D-leu5-enkephalin (DADLE) cross-tolerance after continuous intrathecal infusion in the rat.
Stevens CW; Yaksh TL
Anesthesiology; 1992 Apr; 76(4):596-603. PubMed ID: 1550284
[TBL] [Abstract][Full Text] [Related]
25. The mu rather than the delta subtype of opioid receptors appears to be involved in enkephalin-induced analgesia.
Chaillet P; Coulaud A; Zajac JM; Fournie-Zaluski MC; Costentin J; Roques BP
Eur J Pharmacol; 1984 May; 101(1-2):83-90. PubMed ID: 6086366
[TBL] [Abstract][Full Text] [Related]
26. DSLET (D-ser2-leu5-enkephalin-Thr6) produces analgesia on the hot plate by mechanisms largely different from DAGO and morphine-like opioids.
Belknap JK; Laursen SE
Life Sci; 1987 Jul; 41(4):391-5. PubMed ID: 3298912
[TBL] [Abstract][Full Text] [Related]
27. Heroin acts on different opioid receptors than morphine in Swiss Webster and ICR mice to produce antinociception.
Rady JJ; Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1991 Feb; 256(2):448-57. PubMed ID: 1847196
[TBL] [Abstract][Full Text] [Related]
28. Distinct differences between morphine- and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin-mu-opioid receptor complexes demonstrated by cyclic AMP-dependent protein kinase phosphorylation.
Chakrabarti S; Law PY; Loh HH
J Neurochem; 1998 Jul; 71(1):231-9. PubMed ID: 9648870
[TBL] [Abstract][Full Text] [Related]
29. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome.
Baumeister AA; Richard AL; Richmond-Landeche L; Hurry MJ; Waguespack AM
Neuropharmacology; 1992 Sep; 31(9):835-41. PubMed ID: 1359441
[TBL] [Abstract][Full Text] [Related]
30. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice.
Paul D; Bodnar RJ; Gistrak MA; Pasternak GW
Eur J Pharmacol; 1989 Sep; 168(3):307-14. PubMed ID: 2555205
[TBL] [Abstract][Full Text] [Related]
31. Central opioid receptors and baroreflex control of sympathetic and cardiovascular function.
Gordon FJ
J Pharmacol Exp Ther; 1986 May; 237(2):428-36. PubMed ID: 3009782
[TBL] [Abstract][Full Text] [Related]
32. The effect of morphine tolerance-dependence and abstinence on mu, delta, and kappa opiate receptors of discrete brain regions and spinal cord of the rat.
Bhargava HN; Gulati A
NIDA Res Monogr; 1990; 105():530-1. PubMed ID: 1652091
[No Abstract] [Full Text] [Related]
33. Cardiovascular and respiratory effects of mu-, delta- and kappa-opiate agonists microinjected into the anterior hypothalamic brain area of awake rats.
Pfeiffer A; Feuerstein G; Kopin IJ; Faden AI
J Pharmacol Exp Ther; 1983 Jun; 225(3):735-41. PubMed ID: 6306217
[TBL] [Abstract][Full Text] [Related]
34. Differences in physical dependence induced by selective mu or delta opioid agonists and by endogenous enkephalins protected by peptidase inhibitors.
Maldonado R; Feger J; Fournié-Zaluski MC; Roques BP
Brain Res; 1990 Jun; 520(1-2):247-54. PubMed ID: 2169953
[TBL] [Abstract][Full Text] [Related]
35. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats.
Bagetta G; De Sarro GB; Sakurada S; Rispoli V; Nisticò G
Br J Pharmacol; 1990 Nov; 101(3):655-61. PubMed ID: 1963804
[TBL] [Abstract][Full Text] [Related]
36. Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.
Noble F; Cox BM
Br J Pharmacol; 1996 Jan; 117(1):161-9. PubMed ID: 8825358
[TBL] [Abstract][Full Text] [Related]
37. Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1989 May; 249(2):462-9. PubMed ID: 2566676
[TBL] [Abstract][Full Text] [Related]
38. Intracerebroventricular N-ethylmaleimide differentially reduces supraspinal opioid analgesia in mice.
Sánchez-Blázquez P; Ulibarri I; Garzón J
Eur J Pharmacol; 1989 Jul; 166(2):193-200. PubMed ID: 2676563
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of oxytocin secretion by mu and delta receptor selective enkephalin analogues.
Wright DM; Clarke G
Neuropeptides; 1984 Dec; 5(1-3):273-6. PubMed ID: 6099511
[TBL] [Abstract][Full Text] [Related]
40. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
Kamei J; Ohsawa M; Saitoh A; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
J Pharmacol Exp Ther; 1995 Aug; 274(2):700-6. PubMed ID: 7636731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
